In response to COVID-19, the activation of ECs was also associated with the overexpression of proangiogenic factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2), and placental growth factors (PlGF; Smadja et al., 2021). The gene discussed is FGF2; the disease is COVID-19.